We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Cortisol Predicts Death and Critical Disease

By LabMedica International staff writers
Posted on 12 Dec 2012
Several biomarkers and prognostic scores have been evaluated to predict prognosis in community-acquired pneumonia (CAP).

Serum cortisol concentration is associated with severity and mortality and predicts persistent clinical instability, making it a potential parameter to improve the identification of patients with high risk for a complicated disease course.

Scientists at the University Hospital Carl Gustav Carus (Dresden, Germany) studied 984 hospitalized CAP-patients and measured their serum cortisol concentrations and compared its prognostic accuracy to the leucocyte count, C-reactive protein levels, and the clinical prediction CRB-65 score. Serum cortisol was analyzed by a chemiluminescence immunoassay (Roche Diagnostics; Mannheim, Germany). This assay has a measurement range of 0.5 to 1,750 nmol/L; higher concentrations were analyzed by dilution of the serum sample.

Serum cortisol levels on admission were significantly higher in nonsurvivors at a median of 870 nmol/L when compared to survivors at 602 nmol/L. In patients with critical pneumonia the median was 972 nmol/L compared with a median 598 nmol/L in patients with noncritical pneumonia. In subgroup analyses, cortisol independently predicted critical pneumonia when compared to procalcitonin levels.

A causative microbiological pathogen was detected in 195 patients (20%). Of these, typical bacteria were found in 84 patients (43%), atypical bacteria in 64 (33%), viruses in 29 (15%) and mixed infection in 18 (9%). Streptococcus pneumoniae was the most frequently isolated pathogen and was found in 71 patients (36%).

The authors concluded that cortisol predicts mortality and critical disease in hospitalized CAP-patients independently of clinical scores and inflammatory biomarkers. They recommend that it should be incorporated into trials assessing optimal combinations of clinical criteria and biomarkers to improve initial high-risk prediction in CAP. The study was originally published in April 2012 in the Biomedical Central Journal BMC Infectious Diseases.

Related Links:

University Hospital Carl Gustav Carus
Roche Diagnostics




Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.